Prostatis Group LLC Sells 378 Shares of CME Group Inc. $CME

Prostatis Group LLC lessened its holdings in shares of CME Group Inc. (NASDAQ:CME) by 33.7% during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 745 shares of the financial services provider’s stock after selling 378 shares during the quarter. Prostatis Group LLC’s holdings in CME Group were worth $205,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in CME. Great Lakes Advisors LLC boosted its stake in CME Group by 2.3% during the first quarter. Great Lakes Advisors LLC now owns 1,661 shares of the financial services provider’s stock worth $441,000 after buying an additional 37 shares in the last quarter. Beaumont Financial Advisors LLC boosted its stake in CME Group by 2.0% during the second quarter. Beaumont Financial Advisors LLC now owns 1,952 shares of the financial services provider’s stock worth $538,000 after buying an additional 38 shares in the last quarter. Trifecta Capital Advisors LLC boosted its stake in CME Group by 59.2% during the second quarter. Trifecta Capital Advisors LLC now owns 113 shares of the financial services provider’s stock worth $31,000 after buying an additional 42 shares in the last quarter. OneAscent Financial Services LLC boosted its stake in CME Group by 4.0% during the first quarter. OneAscent Financial Services LLC now owns 1,106 shares of the financial services provider’s stock worth $293,000 after buying an additional 43 shares in the last quarter. Finally, Highline Wealth Partners LLC boosted its stake in CME Group by 84.3% during the second quarter. Highline Wealth Partners LLC now owns 94 shares of the financial services provider’s stock worth $26,000 after buying an additional 43 shares in the last quarter. Institutional investors own 87.75% of the company’s stock.

CME Group Stock Performance

CME Group stock opened at $271.45 on Monday. The stock has a 50-day simple moving average of $268.89 and a 200 day simple moving average of $271.29. The company has a quick ratio of 1.02, a current ratio of 1.02 and a debt-to-equity ratio of 0.12. CME Group Inc. has a 12-month low of $213.94 and a 12-month high of $290.79. The stock has a market capitalization of $97.83 billion, a price-to-earnings ratio of 26.28, a P/E/G ratio of 5.72 and a beta of 0.41.

CME Group (NASDAQ:CME) last released its quarterly earnings results on Wednesday, July 23rd. The financial services provider reported $2.96 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.91 by $0.05. CME Group had a return on equity of 14.60% and a net margin of 58.48%.The business had revenue of $1.69 billion during the quarter, compared to analysts’ expectations of $1.68 billion. During the same period in the previous year, the business posted $2.56 earnings per share. The firm’s revenue for the quarter was up 10.4% compared to the same quarter last year. On average, research analysts anticipate that CME Group Inc. will post 10.49 earnings per share for the current fiscal year.

CME Group Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Thursday, September 25th. Shareholders of record on Tuesday, September 9th were issued a dividend of $1.25 per share. This represents a $5.00 annualized dividend and a yield of 1.8%. The ex-dividend date of this dividend was Tuesday, September 9th. CME Group’s payout ratio is currently 48.40%.

Analysts Set New Price Targets

CME has been the topic of a number of recent research reports. Piper Sandler lifted their price target on shares of CME Group from $283.00 to $296.00 and gave the stock an “overweight” rating in a research note on Tuesday, July 15th. Citigroup upgraded shares of CME Group from a “neutral” rating to a “buy” rating and lifted their price target for the stock from $275.00 to $300.00 in a research note on Thursday, September 25th. UBS Group decreased their price target on shares of CME Group from $305.00 to $285.00 and set a “neutral” rating on the stock in a research note on Monday, September 8th. TD Cowen lifted their price target on shares of CME Group from $281.00 to $288.00 and gave the stock a “hold” rating in a research note on Wednesday, October 8th. Finally, JPMorgan Chase & Co. lifted their price objective on CME Group from $246.00 to $252.00 and gave the company an “underweight” rating in a report on Thursday, September 25th. Seven equities research analysts have rated the stock with a Buy rating, seven have issued a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and an average target price of $281.00.

Insider Transactions at CME Group

In other CME Group news, General Counsel Jonathan L. Marcus sold 392 shares of the business’s stock in a transaction dated Thursday, September 18th. The stock was sold at an average price of $262.00, for a total transaction of $102,704.00. Following the completion of the sale, the general counsel directly owned 7,851 shares of the company’s stock, valued at approximately $2,056,962. The trade was a 4.76% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director William R. Shepard acquired 262 shares of the company’s stock in a transaction on Thursday, September 25th. The shares were purchased at an average cost of $265.19 per share, with a total value of $69,479.78. Following the completion of the acquisition, the director directly owned 258,459 shares in the company, valued at approximately $68,540,742.21. The trade was a 0.10% increase in their position. The disclosure for this purchase can be found here. Over the last quarter, insiders sold 13,043 shares of company stock valued at $3,527,956. 0.30% of the stock is owned by company insiders.

About CME Group

CME Group Inc, together with its subsidiaries, operates contract markets for the trading of futures and options on futures contracts worldwide. It offers futures and options products based on interest rates, equity indexes, foreign exchange, agricultural commodities, energy, and metals, as well as fixed income and foreign currency trading services.